Users online: 78  Small font sizeDefault font sizeIncrease font size Print this article Email this article
Search Again
 Table of Contents
 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Article Access Statistics
 Reader Comments
 Email Alert
 Add to My List
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded255    
    Comments [Add]    
    Cited by others 2    

Recommend this journal

Year : 2011  |  Volume : 2  |  Issue : 1  |  Page : 162

Mycobacterium bovis spondylodiscitis after intravesical Bacillus Calmette-Guérin therapy

1 Division of Neurosurgery, Hôpital Notre-Dame du CHUM, University of Montreal, Montreal, QC, Canada
2 Service of Neurosurgery, Centre Hospitalier Régional de Trois-Rivières, University of Montreal, Montreal, QC, Canada

Correspondence Address:
Daniel Shedid
Division of Neurosurgery, Hôpital Notre-Dame du CHUM, University of Montreal, Montreal, QC
Login to access the Email id

DOI: 10.4103/2152-7806.89879

PMID: 22140647

Get Permissions

Background: Intravesical instillations of live-attenuated Bacillus Calmette-Guérin (BCG) are a well-known and effective method for prevention and treatment of bladder carcinoma and carcinoma in situ. Although considered a safe procedure with rare side effects, local and systemic complications may occur. While long bone ostemolyelitis has been well described, very few reports of BCG spondylodiscitis exist in the literature. Case Description: A 67-year-old man developed low back pain, anorexia, and weight loss 11 months after a 6-week course of intravesical BCG instillations for the treatment of bladder carcinoma in situ. Imaging studies revealed L1-L2 spondylodiscitis with epidural and bilateral psoas abscesses. Tissue cultures obtained by percutaneous computed tomography-guided aspiration were positive for Mycobacterium bovis. Despite triple antituberculous therapy (isoniazid, rifampin, and ethambutol), clinical and radiological progression occurred. Therefore, L1 and L2 corpectomies with extensive debridement were performed, followed by 360° anterior-posterior instrumented fusion. After 20 months of follow-up, the patient remains asymptomatic and recurrence-free. Conclusion: Mycobacterium bovis spondylodiscitis is a rare complication of intravesical BCG therapy. Although medical therapy with antituberculous agents is the first-line treatment, surgical decompression, debridement, and stabilization may be necessary in refractory cases.



Print this article         Email this article